Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)

NCT02564614 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02564614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02564614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
May 2, 2016
Completion date
January 22, 2018
Enrollment
9 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular